Kristin Van Heertum

Kristin Van Heertum

Auto-generated profile, based on publicly available information

Kristin Van Heertum

Nashville Fertility Center, Nashville, TN

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2017 in Fertility Research and Practice
Verified
Journal Article
Open access
PDF file
KHKristin Van Heertum
Kristin Van Heertum
BRBrooke Rossi
Brooke Rossi
Alcohol use is prevalent in the United States. Given that a substantial portion of the drinking population is of reproductive age, it is not uncommon for couples who are attempting conception, or for women who are already pregnant, to be regularly consuming alcohol. Alcohol use is associated with multiple reproductive risks, including having a child with a Fetal Alcohol Spectrum Disorder, increased risk of fetal loss, and decreased chance of live birth. This review serves to examine the risks of alcohol in the context of reproductive health.

1 March 2018 in Birth Defects Research
Verified
Journal Article
Closed access
PDF file
KHKristin Van Heertum
Kristin Van Heertum
RWRachel Weinerman
Rachel Weinerman

6 August 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SHSarah Hmaidan
Sarah Hmaidan
KHKristin Van Heertum
Kristin Van Heertum
SBShreya Bhatia
Shreya Bhatia
JDJennifer Domm
Jennifer Domm
MMMeghann McManus
Meghann McManus
HFHaydar Frangoul
Haydar Frangoul
Recently approved gene therapies for sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT) have expanded therapeutic options. However, myeloablative busulfan is associated with a significant risk of infertility. There is limited data on the safety, feasibility, and outcomes of fertility preservation in this population. We report a single center experience of 40 patients who underwent gene therapy over the past 5 years. The cohort included 23 females (14 with SCD and 9 with TDT) and 17 males (8 with SCD and 9 with TDT). All female subjects underwent successful oocyte retrieval. Those with SCD had a median of 1.3 cycles (range 1-2), while those with TDT had a median of 1.4 cycles (range 1-3). Seven (50%) females with SCD had prior history of a thrombotic event, all of whom received anticoagulation prophylaxis, and none experienced thrombosis during ovarian stimulation. There were no SCD related admissions from the procedure. Among males, the median cryopreserved sperm vials were lower in those with SCD (2 vials, range 1-2) compared to those with TDT (6 vials, range 1-15). Median sperm concentration was also lower in those with SCD 7.1 million/mL (range 0-160) compared to TDT 80.4 million/mL (range 0.9-421). Seventeen females had more than 1 year follow-up and all had evidence of ovarian failure with undetectable anti-Müllerian hormone levels (<0.015 ng/mL). Two male subjects fathered children without the use of cryopreserved samples. Fertility preservation was safe, feasible and should be considered for patients with SCD and TDT prior to gene therapies.

16 August 2017 in Women's Midlife Health
Verified
Journal Article
Open access
PDF file
KHKristin Van Heertum
Kristin Van Heertum
JLJames Liu
James Liu
In the United States, there are an increasing number of couples who are intentionally delaying child-bearing. As the average age of mothers continues to rise, more and more women are being faced with the difficulties of attempting conception at the various stages leading up to the menopausal transition. Not only do the chances of conception drastically decrease after the age of 40 years, but the probability of fetal loss (both early and late in pregnancy) significantly increases during this period as well. The aims of this review include providing an overview of the natural progression of the menopausal transition, examining the importance of appropriate contraception, and identifying the difficulties that women face when attempting conception during this physiologically dynamic stage of life. Finally, we will discuss the non-contraceptive benefits of contraception in preparation for pregnancy during the mid-life.

28 January 2024 in F&S Reports
Verified
Journal Article
Open access
KHKristin Van Heertum
Kristin Van Heertum
EDElizabeth DeVilbiss
Elizabeth DeVilbiss
JGJames Goldfarb
James Goldfarb
SMSunni Mumford
Sunni Mumford
RWRachel Weinerman
Rachel Weinerman
Objective: To compare neonatal outcomes in pregnancies resulting from embryos that have undergone preimplantation genetic testing (PGT) biopsy compared with no biopsy in both fresh and frozen embryo transfers (ETs) and determine whether fi ndings are mediated by multiple births. Design: Retrospective cohort study. Setting: Society of Assisted Reproductive Technologies-Clinical Outcomes Reporting System data, 2014-2015. Patients: Autologous in vitro fertilization treatment cycles using fresh or frozen blastocyst ET, with or without PGT biopsy. Interventions: Not applicable. Main Outcome Measures: Large for gestational age (LGA), small for gestational age, and preterm delivery. Secondary outcomes included high birthweight, low birthweight, and clinical pregnancy measures. Outcomes were evaluated using log-binomial regression models with repeated measures. Models were used to estimate the controlled direct effects of biopsy on birth outcomes that were not mediated by multiple gestations. Results: In fresh ET, biopsy was associated with an increase in LGA (relative risk [RR] 1.45, confidence interval [CI] 1.04-2.02) that persisted in the model mediated for multiple gestation (RR 1.36, 95% CI 1.01-1.83) but was not present in an analysis restricted to elective single ET (RR 0.99, 95% CI 0.91-1.09). In frozen ET, there were no differences in any of the primary outcomes after accounting for multiple gestations. Conclusions: In a large multicenter database, there were no differences in neonatal outcomes after PGT biopsy in frozen ET cycles, and an increase in LGA was noted in fresh transfers that persisted even after accounting for multiple gestations but was not present in analysis restricted to elective single ET. (F S Rep (R) 2024;5:47-54. (c) 2024 by American Society for Reproductive Medicine.)